SCHEMBL3486256

SCHEMBL3486256

Cc1ccn2cc(NC(=O)c3ccccc3)nc2c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.65
HPGD P15428 1/20 0.65
MAPK1 P28482 1/20 0.65
SMN1; SMN2 Q16637 1/20 0.65
MAP3K5 Q99683 3/20 0.53
MAPK13 O15264 1/20 0.52
BRAF P15056 1/20 0.52
KDR P35968 1/20 0.52
MAPK12 P53778 1/20 0.52
MAPK11 Q15759 1/20 0.52
MAPK14 Q16539 1/20 0.52
KDM4E B2RXH2 2/20 0.51
POLB P06746 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
NPC1 O15118 5/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3486577 0.82 KDM4E (0.62) ALDH1A1HPGDSMN1; SMN2MAP3K5MAPK13
SCHEMBL3486348 0.80 MAP3K5 (0.63) ALDH1A1HPGDSMN1; SMN2MAP3K5KDM4E
SCHEMBL4728109 0.79 ALDH1A1 (1.00) ALDH1A1HPGDMAPK1SMN1; SMN2KDM4E
SCHEMBL9184726 0.77 NPC1 (0.52) SMN1; SMN2MAP3K5NPC1RAB9AMEN1
SCHEMBL4225329 0.77 KDM4E (0.59) ALDH1A1HPGDMAPK1SMN1; SMN2KDM4E
SCHEMBL3368094 0.76 RAB9A (0.69) ALDH1A1HPGDMAPK1SMN1; SMN2KDM4E
SCHEMBL14247568 0.76 MAP3K5 (0.73) ALDH1A1SMN1; SMN2MAP3K5MAPK13BRAF
SCHEMBL821848 0.74 MEN1 (0.68) SMN1; SMN2POLBNPC1RAB9ATP53
SCHEMBL3485678 0.73 MAP3K5 (0.73) ALDH1A1HPGDSMN1; SMN2MAP3K5KDM4E
Hydrochloric Acid SCHEMBL28842866 0.72 SMN1; SMN2 (0.53) ALDH1A1HPGDSMN1; SMN2KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029619-A1 FUSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) 2010-02-04 US claimed
EP-2058309-A1 FUSED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-05-13 EP claimed
US-20100029619-A1 FUSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) 2010-02-04 US disclosed
US-20100029619-A1 FUSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) 2010-02-04 US disclosed
US-20100029619-A1 FUSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) 2010-02-04 US disclosed
US-20100029619-A1 FUSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) 2010-02-04 US disclosed
EP-2058309-A1 FUSED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-05-13 EP disclosed
EP-2058309-A1 FUSED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-05-13 EP disclosed
EP-2058309-A1 FUSED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-05-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029619-A1 FUSED HETEROCYCLIC COMPOUND IRAK1, IL1R1, IRAK2 ALDH1A1 794/4885HPGD 1863/4885MAPK1 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.